{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041874","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.131466+00:00","generated_at":"2026-06-08T00:12:22.682187+00:00","sec_items":["2.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AgeX draws $500k from secured note; Serina licenses POZ polymer tech to Pfizer","bullets":["AgeX drew $500k under Amended Secured Convertible Promissory Note with Juvenescence; maturity Feb 14, 2024.","Serina Therapeutics entered non-exclusive license with Pfizer for POZ polymer technology for LNP formulations.","License agreement is potential milestone for Serina, which is merging with AgeX (S-4 filed Nov 14, 2023).","AgeX's merger with Serina remains subject to stockholder and SEC approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041874","json":"https://secwatch.observer/filing/0001493152-23-041874.json","markdown":"https://secwatch.observer/filing/0001493152-23-041874.md","text":"https://secwatch.observer/filing/0001493152-23-041874.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/0001493152-23-041874-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T00:12:22.682187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb5d0af26ba1b3584f8a270305c25ac960863293","claim":"Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On November 15, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited (“Juvenescence”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223041874/0001493152-23-041874-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}